{{Rsnum
|rsid=2240920
|Gene=ITIH3
|Chromosome=3
|position=52796993
|Orientation=minus
|GMAF=0.3889
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ITIH3
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 7.1 | 42.9 | 50.0
| HCB | 14.0 | 56.6 | 29.4
| JPT | 24.1 | 47.2 | 28.7
| YRI | 13.3 | 49.0 | 37.8
| ASW | 0.0 | 0.0 | 0.0
| CHB | 14.0 | 56.6 | 29.4
| CHD | 13.0 | 47.2 | 39.8
| GIH | 8.0 | 41.0 | 51.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 38.6 | 45.6 | 15.8
| MKK | 13.0 | 46.8 | 40.3
| TSI | 22.8 | 53.5 | 23.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2240920
|Name_s=
|Gene_s=ITIH3
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00006. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109419
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2240920
|overall_frequency_n=39
|overall_frequency_d=128
|overall_frequency=0.304688
|n_genomes=32
|n_genomes_annotated=0
|n_haplomes=37
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}